

17. **(Twice Amended)** A method for the detection of ZGGBP1, which comprises measuring the presence or absence of a protein selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and fusions thereof with glutathione-S-transferase.

The amended claims are restated below to reflect changes from the last filing.

10. **(Amended)** A purified polypeptide comprising the amino acid sequence of ~~SEQ ID No 2~~ and homologues and fragments thereof SEQ ID NO:2.

11. **(Amended)** A purified polypeptide comprising the amino acid sequence of ~~SEQ ID No 4~~ and homologues and fragments thereof SEQ ID NO:4.

17. **(Twice Amended)** A diagnostic assay method for the detection of ZGGBP1, which assay comprises measuring the presence or absence of a protein ~~as claimed in claims 10-11~~ selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, and fusions thereof with glutathione-S-transferase.

#### REMARKS

Claims 10-12 and 17 constitute the pending claims in the present application. Applicants cancel, without prejudice, claim 22. Applicants respectfully request reconsideration in view of the following remarks. Issues raised by the Examiner will be addressed below in the order they appear in the prior Office Action.

1-2. Applicants note that the amendments of Paper 10 have been entered, and that claims 10-12, 17 and 22 are under examination in the instant office action.

3. Regarding Applicants' claims for foreign priority, the prior Office Action contends that Applicants have not filed a certified copy of the foreign priority document as required by 35 U.S.C. 119(b). However, Applicants respectfully direct the Examiner's attention to the Notification of Acceptance dated 23 March 2000, a copy of which is enclosed for the Examiner's